Regenxbio (RGNX) Non-Current Assets (2014 - 2026)
Regenxbio (RGNX) posted quarterly Non-Current Assets of $171.8 million for Q4 2025, down 8.64% year-over-year from $188.0 million in Q4 2024, and down 11.12% quarter-over-quarter from $193.2 million in Q3 2025.
Regenxbio (RGNX) Non-Current Assets (2014 - 2026) Analysis & Trends
Regenxbio's Non-Current Assets history runs 12 years deep, the most recent figure standing at $171.8 million for Q4 2025.
- In Q4 2025, Non-Current Assets fell 8.64% year-over-year to $171.8 million; the TTM figure through Dec 2025 stood at $750.0 million (down 11.79% YoY), while the FY2025 annual figure was $171.8 million, down 8.64% from the prior year.
- Non-Current Assets for Q4 2025 stood at $171.8 million, down from $193.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $595.1 million in Q4 2021, with the low at $171.8 million in Q4 2025.
- The 5-year median for Non-Current Assets is $285.8 million (2023), against an average of $323.3 million.
- The sharpest annual moves came in 2021 and 2023: Non-Current Assets jumped 236.26% in 2021, then tumbled 42.73% in 2023.
- Regenxbio's Non-Current Assets stood at $595.1 million in 2021, then fell by 29.88% to $417.3 million in 2022, then slumped by 42.73% to $239.0 million in 2023, then slipped by 21.34% to $188.0 million in 2024, then retreated by 8.64% to $171.8 million in 2025.
- Business Quant data shows RGNX's Non-Current Assets at $171.8 million in Q4 2025, $193.2 million in Q3 2025, and $207.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 150.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 150.46 Mn |
| Dec 31, 2025 | 171.75 Mn |
| Sep 30, 2025 | 193.24 Mn |
| Jun 30, 2025 | 207.28 Mn |
| Mar 31, 2025 | 177.69 Mn |
| Dec 31, 2024 | 187.99 Mn |
| Sep 30, 2024 | 205.72 Mn |
| Jun 30, 2024 | 222.70 Mn |
| Mar 31, 2024 | 233.80 Mn |
| Dec 31, 2023 | 239.00 Mn |
| Sep 30, 2023 | 267.95 Mn |
| Jun 30, 2023 | 303.65 Mn |
| Mar 31, 2023 | 358.63 Mn |
| Dec 31, 2022 | 417.29 Mn |
| Sep 30, 2022 | 447.15 Mn |
| Jun 30, 2022 | 488.02 Mn |
| Mar 31, 2022 | 578.49 Mn |
| Dec 31, 2021 | 595.08 Mn |
| Sep 30, 2021 | 390.23 Mn |
| Jun 30, 2021 | 399.02 Mn |